Corrigendum to "Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023": [Annals of Oncology 34 (2023) 970-986]

Affiliations

¹ Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.
² Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA.
³ Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
⁴ Center for Hematology and Oncology Bethanien, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany.
⁵ Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, Edinburgh, UK.
⁶ International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
⁷ Institut für Pathologie, Philipps-Universität Marburg und Universitätsklinikum Marburg, Marburg, Germany.
⁸ Department of Radiation Oncology, Iridium Netwerk, Wilrijk-Antwerp, Belgium; University of Antwerp, Faculty of Medicine and Health Sciences, Wilrijk-Antwerp, Belgium.
⁹ Department of Surgery, University Hospital Basel, Basel, Switzerland; Faculty of Medicine, University of Basel, Basel, Switzerland.
¹⁰ SwissBreastCare, Bethanienspital, Zürich, Switzerland; SONK Foundation, St. Gallen, Switzerland.

Free article

Published Erratum

G Curigliano et al. Ann Oncol. 2025 Mar.

Free article

. 2025 Mar;36(3):351.

doi: 10.1016/j.annonc.2024.11.001. Epub 2024 Dec 2.

¹ Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.
² Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA.
³ Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
⁴ Center for Hematology and Oncology Bethanien, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany.
⁵ Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, Edinburgh, UK.
⁶ International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
⁷ Institut für Pathologie, Philipps-Universität Marburg und Universitätsklinikum Marburg, Marburg, Germany.
⁸ Department of Radiation Oncology, Iridium Netwerk, Wilrijk-Antwerp, Belgium; University of Antwerp, Faculty of Medicine and Health Sciences, Wilrijk-Antwerp, Belgium.
⁹ Department of Surgery, University Hospital Basel, Basel, Switzerland; Faculty of Medicine, University of Basel, Basel, Switzerland.
¹⁰ SwissBreastCare, Bethanienspital, Zürich, Switzerland; SONK Foundation, St. Gallen, Switzerland.

No abstract available

Erratum for

Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023.
Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, Denkert C, Poortmans P, Weber WP, Thürlimann B; St Gallen Consensus Conference Panelists 2023. Curigliano G, et al. Ann Oncol. 2023 Nov;34(11):970-986. doi: 10.1016/j.annonc.2023.08.017. Epub 2023 Sep 6. Ann Oncol. 2023. PMID: 37683978